Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix®) in adults 55 years of age and over: A sub-analysis of four trials

P Van Damme, P McIntyre, E Grimprel, S Kuriyakose… - Vaccine, 2011 - Elsevier
BACKGROUND: Older adults, especially those over 65 years, are at risk of more severe
morbidity from diphtheria, tetanus and pertussis and may transmit pertussis to unvaccinated …
被引用次数：33 相关文章

[引用][C] Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix®) in adults 55 years of age and over: A sub-analysis of four trials

P VAN DAMME, P MCINTYRE, E GRIMPREL… - Vaccine, 2011 - pascal-francis.inist.fr
Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix®) in adults 55 years
of age and over: A sub-analysis of four trials CNRS Inist Pascal-Francis CNRS Pascal and …

Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix®) in adults 55 years of age and over: a sub-analysis of four trials

P van Damme, P McIntyre… - Vaccine …, 2011 - repository.uantwerpen.be
Background Older adults, especially those over 65 years, are at risk of more severe
morbidity from diphtheria, tetanus and pertussis and may transmit pertussis to unvaccinated …

Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix®) in adults 55 years of age and over: a sub-analysis of four trials.

P Damme, P McIntyre, E Grimprel, S Kuriyakose… - 2011 - cabidigitallibrary.org
Background: Older adults, especially those over 65 years, are at risk of more severe
morbidity from diphtheria, tetanus and pertussis and may transmit pertussis to unvaccinated …

Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix (®)) in adults 55 years of age and over: a sub-analysis of four trials

P Van Damme, P McIntyre, E Grimprel, S Kuriyakose… - 2011 - pubmed.ncbi.nlm.nih.gov
Background Older adults, especially those over 65 years, are at risk of more severe
morbidity from diphtheria, tetanus and pertussis and may transmit pertussis to unvaccinated …

Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix (®)) in adults 55 years of age and over: a sub-analysis of four trials.

P Van Damme, P McIntyre, E Grimprel, S Kuriyakose… - Vaccine, 2011 - europepmc.org
Background Older adults, especially those over 65 years, are at risk of more severe
morbidity from diphtheria, tetanus and pertussis and may transmit pertussis to unvaccinated …

Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix®) in adults 55 years of age and over: A sub-analysis of four trials

P Van Damme, P McIntyre, E Grimprel, S Kuriyakose… - Vaccine, 2011 - infona.pl
Older adults, especially those over 65 years, are at risk of more severe morbidity from
diphtheria, tetanus and pertussis and may transmit pertussis to unvaccinated or not yet fully …

[引用][C] Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix®) in adults 55 years of age and over: A sub-analysis of four trials

P VAN DAMME, P MCINTYRE, E GRIMPREL… - Vaccine, 2011 - Elsevier

[引用][C] Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix®) in adults 55 years of age and over: A sub-analysis of four trials

P van Damme, P McIntyre, E Grimprel, S Kuriyakose… - Vaccine, 2011 - Elsevier Limited

[引用][C] Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix®) in adults 55 years of age and over: A sub-analysis of four trials

P Van Damme, P McIntyre, E Grimprel, S Kuriyakose… - 2011